Durable medical equipment (DME) compliance has long been fertile ground for government scrutiny, but bone growth stimulators present a particularly nuanced—and risky—intersection of reimbursement rules, medical necessity, and marketing practices. A review of enforcement actions, civil litigation, and regulatory guidance reveals recurring compliance failures that should be top of mind for compliance officers overseeing providers, DME suppliers, manufacturers, and clinical relationships.

I’ve worked with compliance teams that passed every audit, maintained clean documentation, and still felt unsure about their real risk exposure. That disconnect shows up more often than we admit.

In fact, 68% of organizations have experienced breaches through third-party risks, despite being compliant on paper. From a compliance perspective, that is not a failure of the framework. It is a gap between what is documented and what is actually happening in the environment.

Digital transformation is no longer optional; organizations across industries are adopting cloud platforms, automation, and AI-driven tools to improve efficiency, customer experiences, and competitiveness. While these innovations bring significant business advantages, they also create new challenges for compliance professionals. Chief among these are data privacy concerns and the need to navigate complex regulatory requirements. Without proper planning, organizations risk legal penalties, reputational damage, and operational disruption.